{
    "Trade/Device Name(s)": [
        "ADVIA Centaur Total IgE (tIgE)"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K193493",
    "Predicate Device Reference 510(k) Number(s)": [
        "K920372"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DGC"
    ],
    "Summary Letter Date": "December 16, 2019",
    "Summary Letter Received Date": "December 17, 2019",
    "Submission Date": "December 13, 2019",
    "Regulation Number(s)": [
        "21 CFR 866.5510"
    ],
    "Regulation Name(s)": [
        "Immunoglobulins A, G, M, D, and E immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology",
        "allergy"
    ],
    "Analyte(s)": [
        "Total IgE"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (EDTA and lithium heparin)"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA Centaur",
        "ADVIA Centaur XP",
        "ADVIA Centaur XPT"
    ],
    "Method(s)/Technology(ies)": [
        "Two-site sandwich immunoassay",
        "Direct chemiluminescent"
    ],
    "Methodologies": [
        "Immunoassay",
        "Chemiluminescent assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Diluent",
        "Curve Material"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA Centaur Total IgE (tIgE) assay adding plasma sample claim and updated detection capability",
    "Indications for Use Summary": "For in vitro diagnostic quantitative determination of total IgE in serum and plasma (EDTA and lithium heparin) using ADVIA Centaur analyzers",
    "fda_folder": "Immunology"
}